Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
CEQ508
print preview
bookmark
share with colleague
General Information
Company
Marina Biotech Inc.
Description
Oral RNAi targeting beta-catenin (CTNNB1) delivered using transKingdom RNAi (tkRNAi) technology
Molecular Target
Beta-catenin (CTNNB1)
Mechanism of Action
Gene silencing
Latest Stage of Development
Phase I/II
Indication
Colorectal cancer
Partner
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy